TB/HIV: Impact and Opportunities Helene Gayle, MD, MPH Bill and Melinda Gates Foundation DATE, 2004.

Slides:

Advertisements

Similar presentations

R&D Financing by the Bill & Melinda Gates Foundation

Advertisements

Stop TB Strategy Planning Frameworks Mukund Uplekar TB Strategy, Operations and Health Systems, Stop TB Department, WHO.

Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.

Bill & Melinda Gates Foundation Male Circumcision funding Heather Harrison WHO meeting June, 2010.

Process and Products of TB/HIV Operational Research Chiang Rai, Thailand Jintana Ngamvithayapong-Yanai, PhD. JSPS-Fellow, Research Institute of Tuberculosis,

Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.

End TB strategy target setting

Anders Chen, MD Internal Medicine R3 4/5/2011.  TB infection control (TB IC): Background  WHO Policy recommendations  Literature review  Practical.

TUBERCOLOSIS Agis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor SEMINAR ON TROPICAL AND TRAVEL MEDICINE AT TTCIH IFAKARA 25 JUNE 2009.

The ninth Technical Advisory Group and National TB Managers meeting

Tuberculosis in Children and Young Adults

Dollars and disease Marrying social, economic and disease dynamic perspectives for public health Nim Arinaminpathy Imperial College London.

Module 1: Course Overview. Course Objectives Teach you everything you need to know about the TB Program Describe TB the roles and responsibilities of.

Unit 5: IPT Isoniazid TB Preventive Therapy

Standard of Care for MDR-TB

Tools for HIV/TB Integration and the Civil Society Experience Carol Nawina Nyirenda Executive Director Community Initiative for Tuberculosis, HIV/AIDS.

22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.

African Business Leaders on Health GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 2010 Technical Assistance.

Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.

Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director

Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.

PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,

Bi-State TB Elimination April 10, 2014 Anna Frye Michelle Goodyear Tuberculosis: Recent Trends and Relevant Research.

DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.

FORGOTTEN BUT NOT GONE International Journalists as Global Health Advocates Lee Reichman, MD, MPH Berlin, Germany November 2010.

T reatment A ction G roup Update on Global TB Research By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis.

Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.

Isoniazid preventive therapy for people living with HIV: Public health challenges and implementation issues Peter Godfrey-Faussett UNAIDS (with thanks.

WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.

The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.

FIND Ongoing Activities What’s in the pipeline for Rapid DST? WHO Stop TB Department Supranational Reference Laboratory Network Meeting Paris, October.

Ecdc.europa.eu Tommi Asikainen, Tubingen, 22 October 2008 European Centre for Disease Prevention and Control FUTURE DISEASE CHALLENGES IN EUROPE – where.

Smear negative TB and HIV: urgent research priorities to inform a rolling global policy Haileyesus Getahun, MD, MPH, PhD Stop TB Department WHO/HQ.

African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.

Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.

1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 2: BACKGROUND ON TUBERCULOSIS Insert country/ministry.

Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.

Christo van Niekerk, M.D. Senior Director, Clinical Development Pretoria, South Africa Innovating TB Treatment: Opportunities for Private Sector Engagement.

Colleen Daniels Stop TB Department World Health Organisation TB, HIV and Drug Use The overview.

Strategic Information and the Control of Tuberculosis Brian Williams and Chris Dye TB programme, Monitoring and Evaluation, WHO.

California Update : TB Epidemiology and Indicators CTCA October 22, 2010 Jennifer Flood MD MPH Chief, Surveillance and Epidemiology Tuberculosis Control.

TB HIV Research Perspectives of The Union Riitta Dlodlo, MD, MPH HIV Programme Coordinator The International Union Against Tuberculosis and Lung Disease.

HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.

Tuberculosis in Children and Young Adults

SUMMARY OF IMPLEMENTATION RESULTS TB Project Round 1 Strengthening access to WHO Standard TB Care and Services for Marginalized Population, Cross-border.

Herpes Simplex Virus Type 2 infection among U.S. military service members: Public Health Implications and Opportunities for HIV Prevention Christian T.

Tuberculosis - the opportunity in our lifetime Dr. Lucica Ditiu | Executive Secretary | Stop TB Partnership 09.April.2013 | Brussels, Belgium.

SuPAR and sICAM-1 as Immune Markers for Treatment Response in Ethiopian TB patients with and without HIV co-infection Wegene T. Mekasha ICASA, Addis Ababa.

CQUIN: The HIV Coverage, Quality, and Impact Network Miriam Rabkin, MD, MPH Director for Health Systems Strategies ICAP Columbia University.

The CQUIN Learning Network: Partnering to Advance Differentiated Care

State of the TB Alliance

Richard hayes London school of hygiene & Tropical Medicine

Surveillance. Public Health Approach Surveillance What is the Problem ? Problem Risk Factor Identification : What Is the Cause ? Intervention Evaluation.

TUBERCULOSIS, TB/HIV & MDR-TB

Stop TB Partnership Secretariat (TBP)

Common Messaging Platform

Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.

Pre-conference Meeting Report

Vaccine and Infectious Disease Institute

Knowledge gaps in formulating TB Control Policies for Prisons

TB Strategy & Health Systems (TBS) TB Monitoring & Evaluation (TME)

C R E A E Consortium to Respond Effectively to the AIDS-TB Epidemic

Epidemic of Lung Cancer in Patients With HIV Infection

Situational Analysis for implementing TB/HIV Surveillance in Ethiopia

Expert Group on HIV/STI

The STOP TB Strategy – 2009 VISION: A TB-free world

A Single Participant Exposed Twice to an Inflammatory Stimulus

TB-HIV/AIDS Co-Infection Coordination among Programs

Strategic framework for TB/HIV

Presentation transcript:

TB/HIV: Impact and Opportunities Helene Gayle, MD, MPH Bill and Melinda Gates Foundation DATE, 2004

Small and Fujiwara, N Eng J Med 343:189, 2001 The annual risk of TB in HIV infected approximates the lifetime risk of HIV uninfected HIV/TB: Profound Effect on Individuals

HIV/TB: Profound Effect on Populations Kenyon et al., Int J TB Lung Dis 1999;3:4-11

HIV/TB: Profound Effect on Populations WHO TB Surveillance Report, 2003

TB/HIV Co-Authorship Network Medline TB 12,352 TB 12,352 HIV 43,455 HIV 43,455 “Top” 50 authors Separate Responses Abernethy and Small, unpublished

A Coordinated Response C R E A E To design, implement and evaluate a portfolio of community level trials of new strategies to reduce tuberculosis incidence in populations with high rates of HIV and TB co-infection.

TB/HIV Ultimate Need for New Tools FIND/TDR for diagnostics ($30M) Global Alliance for new drug ($25 M) Aeras for vaccines ($83M) Reaping the benefits of science